Successful Rechallenge with Osimertinib following Osimertinib-Induced Ventricular Tachycardia: A Case Report

Osimertinib, a third-generation tyrosine kinase inhibitor, is the first-line treatment for metastatic non-small cell lung cancer (NSCLC) with sensitizing epidermal growth factor receptor (EGFR) mutations. It is known to cause drug-induced cardiotoxicity, including QT prolongation syndrome, heart fai...

Descripción completa

Detalles Bibliográficos
Autores principales: Saito, Zentaro, Imakita, Takuma, Ito, Takanori, Oi, Issei, Kanai, Osamu, Fujita, Kohei, Tachibana, Hiromasa, Mio, Tadashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601787/
https://www.ncbi.nlm.nih.gov/pubmed/37900846
http://dx.doi.org/10.1159/000533826

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601787/
https://www.ncbi.nlm.nih.gov/pubmed/37900846
http://dx.doi.org/10.1159/000533826

Ejemplares similares